Mergers & Acquisitions ·
Indivior and Supernus update merger proxy with supplemental disclosures amid stockholder litigation
INDVSupernus, Inc.
Indivior Pharmaceuticals and Supernus Pharmaceuticals filed a supplement to their joint proxy statement/prospectus regarding the proposed merger. The filing updates valuation analyses by financial advisor Cantor Fitzgerald, adjusting for estimated cash, debt, and a $1 billion special dividend paid by Indivior. This disclosure follows demand letters and complaints from purported stockholders alleging incomplete information in the original proxy materials. Both companies deny any wrongdoing but voluntarily supplemented the disclosures to moot litigation claims and avoid delays to the merger. Special meetings of stockholders for both companies are scheduled for October 15, 2026, to vote on the transaction. Indivior Pharmaceuticals is a pharmaceutical company focused on addiction treatment therapies.